The LZTS1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line. This product provides a heterogeneous pool of cells with targeted LZTS1 gene disruption, enabling loss-of-function studies without clonal isolation. The polyclonal format maintains genetic diversity, offering a more representative model of tumor cell populations for comparative research against wild-type controls.
Raji cells are an EBV-positive Burkitt lymphoma line with a t(8;14) translocation that drives MYC overexpression. These B lymphocytes exhibit lymphoblastoid features and retain antigen presentation and antibody production functions, making them a key model in immunology and hematological malignancy research. The EBV-driven immortalization and constitutive activation of survival pathways provide a relevant context for studying tumor suppressor loss.
LZTS1 is a tumor suppressor that negatively regulates Wnt/??-catenin signaling by interacting with ??-catenin to prevent its nuclear translocation and promote degradation, thereby repressing ??-catenin/TCF-mediated transcription of MYC and CCND1. LZTS1 also inhibits AKT activity, reducing survival signals and promoting apoptosis via BCL2 downregulation and BAD/caspase activation. Upstream, p53 transcriptionally regulates LZTS1, while miR-135a/b and DNA methylation suppress its expression. The protein further interacts with Cdk1 and 14-3-3, linking cell cycle and survival pathways.
In the Raji lymphoma background, LZTS1 knockout amplifies Wnt/??-catenin and PI3K/AKT/mTOR signaling, synergizing with constitutive MYC expression and EBV-driven proliferation. This polyclonal knockout model mirrors tumor heterogeneity, enabling investigation of how LZTS1 loss cooperates with oncogenic events to deregulate B-cell growth and apoptosis. It is particularly suited for studying drug resistance mechanisms due to the mixed population’s diverse editing profiles.
Typical applications include Western blotting for ??-catenin, AKT, and phospho-AKT; RT-qPCR for MYC, CCND1, and BCL2; flow cytometry for apoptosis and cell cycle; co-immunoprecipitation of LZTS1-??-catenin complexes; drug sensitivity assays with doxorubicin or ibrutinib; and immunofluorescence to assess ??-catenin localization. This knockout tool supports B-cell lymphoma research, pathway crosstalk analysis, and therapeutic target identification. For inquiries, please contact Ascent Research.
